Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

To join this study, you must be an adult aged 18 or older and have a confirmed diagnosis of IgA Nephropathy through a kidney biopsy. You also need to have certain levels of protein in your urine, showing your kidneys are affected, and your kidney function must be at a particular level, not too severely reduced.

There are also some things that would mean you can't join. For example, if you've recently had other treatments that affect your immune system, like certain steroids or other immune-suppressing medicines, you might not be able to take part. Also, if your kidney function has worsened very quickly in the past few months, the study might not be suitable for you.

Your doctor will check all the specific details to see if this study is the right fit for your health situation.

If you decide to join this study, you will either receive the new medicine, povetacicept, or a dummy medicine called a placebo. You won't know which one you are getting, and neither will your study doctor, until the study is over. You'll need to attend regular clinic visits where the study team will monitor your health, check your kidney function through blood tests, and measure the amount of protein in your urine. These checks will help doctors understand how the medicine is working and whether it's safe for you. The total duration of your participation in the study will be explained in detail by the study team, including how often you'll need to visit and for how long. You will also have follow-up appointments after you stop taking the study medicine to ensure your well-being.